

Docket No: PVI-5813CP1CN1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Langberg et al.	Art Unit: 3738
App. No.: 10/715221	Examiner: Stewart, Jason-Dennis Neilken
Conf. No.: 5022	Title: PERCUTANEOUS MITRAL- ANNULOPLASTY WITH CARDIAC RHYTHM MANAGEMENT
Filing Date: November 17, 2003	

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, and §§ 1.97 - 1.987 as supplemented by MPEP § 609, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08A. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the Form PTO/SB/08A be considered by the Examiner and made of record.

A list of the enclosed documents is provided in Form PTO/SB/08A, transmitted herewith. Presentation of documents listed on the aforementioned form is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This Information Disclosure Statement does not include copies of cited U.S. patents and U.S. patent publications pursuant to 37 C.F.R. 1.98(a)(2).

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is considered to be material to patentability, or that no other material information exists.

After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement. The Commissioner is hereby authorized to charge Deposit Account No. 50-1225 for the fee (\$180.00) set forth in 37 C.F.R. § 1.17(p) and any additional required fees (Docket No. PVI-5813CP1CN1).

Respectfully submitted,

EDWARDS LIFESCIENCES LLC

Dated: Jan. 3, 2011

By: 

Melinda Michalerya, Esq.
Reg. No. 59,654
Edwards Lifesciences LLC
Law Department
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-6801
Facsimile: (949) 250-6850

Enclosures:
Form PTO-SB-08A